November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Evaluating Adjuvant Pembrolizumab for Triple-Negative Breast Cancer Post-Chemotherapy

🧠 AI Analysis 2 min read 👁 1

Medical experts preview upcoming clinical trial data examining whether post-surgery immunotherapy can lower recurrence risks for high-risk breast cancer patients.

Evaluating Adjuvant Pembrolizumab for Triple-Negative Breast Cancer Post-Chemotherapy🧠AI Analysis

Photo: medpagetoday.com

Key points

  • Phase III SWOG-S1418/NRG Oncology BR006 trial explores adjuvant pembrolizumab
  • Focuses on triple-negative breast cancer patients with residual disease post-chemotherapy
  • Weighs recurrence-free survival against potential permanent immune-related toxicities

An upcoming presentation at the San Antonio Breast Cancer Symposium is set to shed light on whether adding the immunotherapy drug pembrolizumab, marketed as Keytruda, after surgery can improve outcomes for patients with triple-negative breast cancer who still have residual disease following neoadjuvant chemotherapy. Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care, discussed the phase III SWOG-S1418/NRG Oncology BR006 trial in a recent interview, highlighting questions surrounding postoperative anti-PD-1/PD-L1 therapy efficacy.

While preoperative immunotherapy has previously demonstrated improvements in pathologic complete response rates and event-free survival, the effectiveness of continuing such treatment post-surgery has remained uncertain. Previous trials involving other agents, such as avelumab in the A-BRAVE study, did not show a clear benefit, leaving clinicians to rely primarily on standard options like capecitabine or targeted therapy for specific BRCA mutations. This new trial specifically investigates high-risk individuals with residual tumors measuring at least a centimeter, irrespective of their initial PD-L1 status.

Evaluating the balance between therapeutic gains and potential immune-related adverse events remains a critical component of the upcoming findings. Researchers plan to examine specific patient subgroups based on nodal burden and biomarker expression to better understand who might benefit most. Because checkpoint inhibitors can sometimes trigger long-lasting toxicities such as pneumonitis, endocrinopathies, or diabetes, weighing these risks carefully is essential for patient counseling.

What to know: The upcoming trial results aim to clarify if postoperative pembrolizumab reduces recurrence rates for high-risk triple-negative breast cancer patients, though clinicians must carefully weigh potential long-term immune-related toxicities. Always consult a qualified oncologist for personalized medical decisions.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/sabcsfuturefocus/123901 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.